Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy
نویسندگان
چکیده
منابع مشابه
Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
Diabetic nephropathy is a leading cause of end-stage renal disease, which is increasing in incidence worldwide, despite intensive treatment approaches such as glycemic and blood pressure control in patients with diabetes mellitus. New therapeutic strategies are needed to prevent the onset of diabetic nephropathy. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear t...
متن کاملRole of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy
With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Gi...
متن کاملPeroxisome Proliferator-activated Receptors
Peroxisome proliferator-activated receptors (PPARs) are members of the ligand-activated nuclear hormone receptor superfamily of transcription factors that includes receptors for steroids, thyroid hormone, retinoic acid, and vitamin D. Upon activation in the cytoplasm, PPARs heterodimerize with retinoid X receptors (RXR) and form a complex that translocates to the nucleus and regulates gene expr...
متن کاملPeroxisome proliferator-activated receptors and cardiovascular remodeling.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that heterodimerize with the retinoid X receptor and then modulate the function of many target genes. Three PPARs are known: alpha, beta/delta, and gamma. The better known are PPAR-alpha and PPAR-gamma, which may be activated by different synthetic agonists, although the endogenous ligands are unknown. PPAR-alpha is invol...
متن کاملFibrates, glitazones, and peroxisome proliferator-activated receptors.
Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Basic & Clinical Pharmacology
سال: 2019
ISSN: 2279-0780,2319-2003
DOI: 10.18203/2319-2003.ijbcp20194285